Phase II Data May Put Merck Right On Gilead’s Heels In HCV Combo Race
This article was originally published in The Pink Sheet Daily
Executive Summary
At EASL, Merck unveiled new data from a two-drug combination in hepatitis C that may position it as the main competitor to Gilead’s expected dominance in genotype 1 patients.